NeuroDerm's ND0612 Study Evaluates Safety and Pharmacokinetics in Parkinson's Disease
A randomized, placebo-controlled study is underway to assess the safety and pharmacokinetics of ND0612 in Parkinson's disease patients.
Asset / Drug
Drug and asset intelligence for ND0612 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.